Effect of Various Invitation Schemes on the Use of Fecal Immunochemical Tests for Colorectal Cancer Screening: Protocol for a Randomized Controlled Trial

被引:1
|
作者
Gruner, Laura Fiona [1 ,2 ]
Hoffmeister, Michael [1 ]
Ludwig, Leopold [3 ]
Brenner, Hermann [1 ,4 ,5 ,6 ]
机构
[1] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Neuenheimer Feld 581, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Med Fac Heidelberg, Heidelberg, Germany
[3] Gastroentereol Schwerpunktpraxis, Dornstadt, Germany
[4] German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany
[5] Natl Ctr Tumor Dis, Heidelberg, Germany
[6] German Canc Res Ctr, German Canc Consortium, Heidelberg, Germany
来源
JMIR RESEARCH PROTOCOLS | 2020年 / 9卷 / 04期
关键词
colorectal cancer; early detection; screening; fecal immunochemical test (FIT); invitation; Germany; PARTICIPATION;
D O I
10.2196/16413
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Fecal occult blood testing has been offered for many years in the German health care system, but participation rates have been notoriously low. Objective: The aim of this study is to evaluate the effect of various personal invitation schemes on the use of fecal immunochemical tests (FITs) in persons aged 50-54 years. Methods: This study consists of a three-armed randomized controlled trial: (1) arm A: an invitation letter from a health insurance plan including a FIT test kit, (2) arm B: an invitation letter from a health insurance plan including an offer to receive a free FIT test kit by mail upon easy-to-handle request (ie, by internet, fax, or reply mail), and (3) arm C: an information letter on an existing colonoscopy offer (ie, control). Within arms A and B, a random selection of 50% of the study population will receive reminder letters, the effects of which are to be evaluated in a substudy. Results: A total of 17,532 persons aged 50-54 years in a statutory health insurance plan in the southwest of Germany-AOK Baden-Wuerttemberg-were sent an initial invitation, and 5825 reminder letters were sent out. The primary end point is FIT usage within 1 year from receipt of invitation or information letter. The main secondary end points include gender-specific FIT usage within 1 year, rates of positive test results, rates of colonoscopies following a positive test result, and detection rates of advanced neoplasms. The study was launched in September 2017. Data collection and workup were completed in fall 2019. Conclusions: This randomized controlled trial will provide important empirical evidence for enhancing colorectal cancer screening offers in the German health care system.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Making FIT Count: Maximizing Appropriate Use of the Fecal Immunochemical Test for Colorectal Cancer Screening Programs
    Vivy T. Cusumano
    Folasade P. May
    Journal of General Internal Medicine, 2020, 35 : 1870 - 1874
  • [22] Performance of the Fecal Immunochemical Test for Colorectal Cancer Screening Using Different Stool-Collection Devices: Preliminary Results from a Randomized Controlled Trial
    Shin, Hye Young
    Suh, Mina
    Baik, Hyung Won
    Choi, Kui Son
    Park, Boyoung
    Jun, Jae Kwan
    Hwang, Sang-Hyun
    Kim, Byung Chang
    Lee, Chan Wha
    Oh, Jae Hwan
    Lee, You Kyoung
    Han, Dong Soo
    Lee, Do-Hoon
    GUT AND LIVER, 2016, 10 (06) : 925 - 931
  • [23] Moderators of the effectiveness of an intervention to increase colorectal cancer screening through mailed fecal immunochemical test kits: results from a pragmatic randomized trial
    Elizabeth A. O’Connor
    William M. Vollmer
    Amanda F. Petrik
    Beverly B. Green
    Gloria D. Coronado
    Trials, 21
  • [24] Making FIT Count: Maximizing Appropriate Use of the Fecal Immunochemical Test for Colorectal Cancer Screening Programs
    Cusumano, Vivy T.
    May, Folasade P.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (06) : 1870 - 1874
  • [25] HPV self-sampling in cervical cancer screening: the effect of different invitation strategies in various socioeconomic groups - a randomized controlled trial
    Tranberg, Mette
    Bech, Bodil Hammer
    Blaakaer, Jan
    Jensen, Jorgen Skov
    Svanholm, Hans
    Andersen, Berit
    CLINICAL EPIDEMIOLOGY, 2018, 10 : 1027 - 1036
  • [26] The effect of a supplementary ('gist-based') information leaflet on colorectal cancer knowledge and screening intention: a randomized controlled trial
    Smith, Samuel G.
    Raine, Rosalind
    Obichere, Austin
    Wolf, Michael S.
    Wardle, Jane
    von Wagner, Christian
    JOURNAL OF BEHAVIORAL MEDICINE, 2015, 38 (02) : 261 - 272
  • [27] Colorectal cancer screening with fecal immunochemical testing or primary colonoscopy: An analysis of health equity based on a randomised trial
    Stromberg, U.
    Bonander, C.
    Westerberg, M.
    Levin, L. A.
    Metcalfe, C.
    Steele, R.
    Holmberg, L.
    Forsberg, A.
    Hultcrantz, R.
    ECLINICALMEDICINE, 2022, 47
  • [28] Reduced and Full-Preparation CT Colonography, Fecal Immunochemical Test, and Colonoscopy for Population Screening of Colorectal Cancer: A Randomized Trial
    Sali, Lapo
    Mascalchi, Mario
    Falchini, Massimo
    Ventura, Leonardo
    Carozzi, Francesca
    Castiglione, Guido
    Delsanto, Silvia
    Mallardi, Beatrice
    Mantellini, Paola
    Milani, Stefano
    Zappa, Marco
    Grazzini, Grazia
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (02):
  • [29] Colorectal Cancer Screening by Fecal Immunochemical Tests (FIT): Considerations on Sampling and Markers (Hb and Hb/Hp Complex) of Fecal Occult Blood (FOB)
    Syrjaenen, Kari
    Eskelinen, Maaret
    Meklin, Jannica
    Hendolin, Panu
    Eskelinen, Matti
    Suovaniemi, Osmo
    ANTICANCER RESEARCH, 2024, 44 (04) : 1513 - 1523
  • [30] Virtual colonoscopy, optical colonoscopy, or fecal occult blood testing for colorectal cancer screening: results of a pilot randomized controlled trial
    You, John J.
    Liu, Yudong
    Kirby, John
    Vora, Parag
    Moayyedi, Paul
    TRIALS, 2015, 16